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Joshua Kellner1,2, Bei Liu1,2, Yubin Kang1,3 and Zihai Li1,2,3*Abstract: Multiple Myeloma (MM) is a debilitating disease of proliferating and malignant plasma cells that is
currently incurable. The ability of monoclonal recurrence of disease suggests it might arise from a stem cell-like
population capable of self-renewal. The difficulty to isolate the cancer stem-like cell in MM has introduced confusion
toward this hypothesis. However, recent evidence has suggested that MM originates from the B cell lineage with
memory-B cell like features, allowing for self-renewal of the progenitor-like status and differentiation to a monoclo-
nal plasma cell population. Furthermore, this tumor-initiating cell uses signaling pathways and microenvironment
similar to the hematopoietic stem cell, though hijacking these mechanisms to create and favor a more tumorigenic
environment. The bone marrow niche allows for pertinent evasion, either through avoiding immunosurveillance or
through direct interaction with the stroma, inducing quiescence and thus drug resistance. Understanding the inter-
action of the MM stem cell to the microenvironment and the mechanisms utilized by various stem cell-like popula-
tions to allow persistence and therapy-resistance can enable for better targeting of this cell population and
potential eradication of the disease.Background
Stem cells are classified as cells that are pluripotent and
can propagate the cells of a specific lineage while also
maintaining self-renewal. Recent evidence has suggested
that cancer has exploited this unique machinery and
contains a stem-like population that maintains and
propagates disease. The current paradigm regarding the
cancer stem cell (CSC) is that the tumor either arises
from a normal stem cell or inherently contains a
“tumor” stem cell that drives tumor formation. However,
it is debatable if these paradigms can apply to all cancers
or if they are unique to several specific cancer types.
Two initial studies laid claim to the hypothesis of CSCs.
Bergsagel et al. characterized a low frequency population
with tumorigenicity in a plasma cell tumor model of in-
flammation which led to studies where murine myeloma
cells, isolated from ascites, could form in-vitro colonies
at a ratio of only 1 in 10,000 to 1 in 100 cells [1,2]. Vari-
ous solid tumors, such as lung and ovarian cancer, also
exhibited a high degree of tumor-initiating heterogeneity
with only a small subset of the tumor population* Correspondence: zihai@musc.edu
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stated.exhibiting clonogenic potential [3]. The development of
an in vitro assay to study human myeloma clonogenic
cells furthered the work delving into the hypothesis of a
progenitor cancer cell [4]. However, it was the work
from Dick and colleagues who identified a CSC from a
specific subset of acute myelogenous leukemia (AML)
cells that had demonstrated the clonogenic activity of a
particular isolated population with confidence [5]. This
minute population, demonstrating a varied frequency of
about 0.2% in some patients, was capable of transfer dis-
ease into immunodeficient NOD/SCID mice. These
studies suggest the presence of a CSC but it is difficult
to determine whether they are generated from a muta-
tional hit on normal stem cells or from a specific primi-
tive tumor stem cell. The ability to isolate primitive
hematopoietic stem cells (HSC) and our understanding
of the stem-like mechanisms of HSCs has enabled better
understanding of CSCs in leukemias but has proven to
be more difficult in myeloma.Pathology of disease
MM is an incurable blood malignancy characterized by
extensive proliferation of plasma cells (PC) and display-
ing an incidence of about 20,000 annually in the United
States [6]. The tumorigenic PCs secrete monoclonal im-
munoglobulin and induce a wide range of pathologyLtd. This is an Open Access article distributed under the terms of the Creative
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deficiency, anemia and kidney and bone marrow (BM)
dysfunction [7]. Nearly all MM patients derive from
asymptomatic monoclonal gammopathy of undeter-
mined significance (MGUS). Patients could present as
smoldering MM phase that then progresses to advanced
symptomatic phases of MM, which include an active, re-
lapsing and refractory periods [8]. Various treatments
for MM have been developed including corticosteroids,
DNA alkylating agents, immune-modifying drugs, prote-
asome inhibitors and hematopoietic stem cell transplant-
ation (SCT). Over the last decade, the overall survival of
MM patients has improved from a median of 3–4 years
to currently at 5–7 years, largely due to the use of sev-
eral highly active chemoagents and the incorporation of
autologous HSC transplantation. However, almost all
MM patients will relapse [9]. This high relapse rate in
MM patients has suggested the possibility of a CSC that
can drive disease progression.
Evidence for the multiple myeloma stem cell
Background
The supposition of a multiple myeloma stem cell
(MMSC) has been made for a few decades but identifica-
tion of the exact cell or population has been difficult to
accomplish. Biologically, B cells are derived from the
common lymphoid progenitor cell and driven through
pro-B to pre-B cell subsets by activation of transcription
factors and subsequent expression of the μ chain im-
munoglobulin and rearrangement of the heavy chain.
Development then moves to secondary lymphoid organs
(i.e. spleen, lymph nodes) where exposure to antigens in-
duces generation of germinal centers, somatic hyper-
mutation at the Ig locus and proliferation to create
clonal-specific memory and short-term and long-term
antibody-secreting plasma cells (PCs) that can respond
to subsequent antigen exposures. Memory and long-
term PCs reside in the BM where they receive support
from the BM stroma for survival and activation. The
specific cell population, within the B cell/PC lineage,
that contains the supposed MM CSC, however, is still
unknown.
Cellular identification
The key cellular component of MM, the monoclonal
(M) protein-secreting plasma cell, is a terminally differ-
entiated cell type that arises from the B cell lineage. The
pathological highlights of MM suggest, however, that
malignancy is incurred in B cells and not in the plasma
cell population. Early studies demonstrated that in
MGUS and MM patients, a fraction of B cells, branded
as clonotypic B cells, were present at differentiated
states; though this population exhibited heterogeneity
[10,11]. Additionally, Bergsagel et al. identified theseclonotypic cells in assorted numbers among patients,
with steady levels observed during treatment but signifi-
cantly higher levels during relapse states [12]. These cir-
culating B cells also had chromosomal aberrations and
Ig rearrangements particular to a certain idiotype seen
in the malignant PC [13-15]. These cells also could dif-
ferentiate into antibody secreting plasma cells suggesting
that the progenitor population of myeloma is contained
in the B cell fraction and has progenitor-like characteris-
tics [16]. Further studies of these B cells identified som-
atic hypermutation in the VDJ region of the genome
with deficiency of intraclonal variation suggesting a
post-germinal center B cell [10,17]. Phenotypic studies
of these circulating clonotypic B cells demonstrated that
they resembled memory B cells, a post-germinal center,
pre-plasma cell generated to establish long-term immun-
ity [18]. This property along with the ability to self-
renew suggested that this phenotype may be the popula-
tion containing the malignant myeloma stem cell but
the research by Rasmussen et al. [18] has been the only
reported suggestion of memory B cells as the myeloma
CSC population.
Biological characteristics
Biological activity of the proposed MMSCs has been
variable due to the plasticity of the surface markers and
the assay used to determine clonogenic activity. This has
led to some confusion regarding the surface marker
phenotype of the MMSC population (summarized in
Table 1). The first model to understand the biology of
myeloma stem cells was done by directly injecting mye-
loma cells from the BM of patients into a subcutane-
ously implanted human fetal bone chip in SCID mice
(named as SCID-hu) [19]. These mice developed clinical
characteristics of MM, such as hypercalcemia and circu-
lating M protein. In a later study, it was reported that
cells from reconstituted SCID-hu mice were able to en-
graft secondary SCID recipients, which validates the
transferable phenotype of a stem cell population [20].
However, the engrafted population was primarily a
CD38++CD45- surface phenotype and no CD19+ B cell
was capable of growth [20]. A secondary study has also
identified the CD19-CD45-CD38 + CD138+ population
as being the tumorigenic stem-like population for MM
in another mouse model [21].
In stark contrast though, Pilarski et al. isolated clono-
typic circulating B cells from a progressed MM patient,
with the ability to engraft immunodeficient mice and
demonstrating clinical phenotypes of lytic bone disease
and the presence of circulating M-protein [22]. Fur-
thermore, this leukemic B cell had Ig rearrangements
identical to the CD138+ plasma cell, suggesting the
involvement of the CD19+ B cell as the progenitor
population [14]. The ability to transfer into secondary
Table 1 List of cell surface markers utilized to identify proposed multiple myeloma stem cell
Phenotype References
CD19 + CD38-CD27+ Rasmussen, T et al., Leukemia and Lymphoma 2004 [18]
CD19 + CD138- Pilarski, LM et al., Blood 2000 [22]
Pilarski, LM et al., Exp Hematology 2002 [23]
Matsui, W et al., Blood 2004 [24]
CD19 + CD138-CD27+ Matsui, W et al., Cancer Research 2008 [25]
CD138-ALDH+ Reghunathan, R et al., Oncotarget 2013 [26]
Matsui, W et al., Cancer Research 2008 [25]
CD19 + CD34-Lchain(λ) + ALDH+ Boucher, K et al., Clinical Cancer Research 2012 [55]
CD38 + CD45- Yaccoby, S et al., Blood 1999 [20]
CD19-CD45-CD38 + CD138+ Kim, D et al., Leukemia 2012 [21]
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this study was subsequently followed to better ascer-
tain the surface marker phenotype of the myeloma
CSC. CD19+ cells lacking the plasma cell marker,
CD138/syndecan1, were able to give rise to the tumor
population in NOD/SCID mice generating both CD19+
and CD138+ myeloma cells [23]. This further sug-
gested that the myelomagenic population was con-
tained in the B cell lineage but not in the plasma
cell pool.
Another study confirmed the lack of CD138 expres-
sion in the MMSC phenotype, as primary myeloma BM
samples expressing CD138+ were unable to engraft
NOD/SCID mice, with the engraftment potential con-
tained solely in the CD138- cell population, incurring
plasma cell proliferation and inducing production of M
protein in vivo [24]. In vitro colony forming assays fur-
ther demonstrated the clonogenic capacity of CD138-
and not CD138+ cells validating the in vivo transplant-
ation studies. Additional studies to identify the cell sur-
face subset of myeloma CSCs found that the cells
resembled a memory B subset in that the clonogenic
population expressed CD19 + CD27 + CD138 [25]. This
population, obtained from peripheral blood of myeloma
patients, engrafted NOD/SCID animals and was trans-
ferrable to secondary recipients as the CD19+ cells from
the BM of the primary mice engrafted. Additionally, the
potential validity of CD138- MMSC and “stemness” has
been described by Reghunathan et al. using human MM
cell lines to demonstrate the CD138- MMSC neoplasti-
city [26].
Though research suggests conflicting subsets in iden-
tification of the MMSC, the issue may be simply due
to the source of the cells, the isolation procedure of
these cells or the in vivo or in vitro assay used to de-
termine potential clonogenicity and progenitor status.
Collectively, however, the MMSC population appears
to reside in the B cell lineage but not in the plasma
cell pool.Signaling pathways
CSCs utilize many of the pathways that regulate and
maintain normal stem cells, adapting the ability to self-
renew to maintain the malignancy. A feature identified
from embryonic stem cells (ESC) to HSCs is the use of
pathways established in many developmental mecha-
nisms, including Hedgehog (Hh), Wnt and Notch path-
ways. Early reports demonstrated the role of these
pathways in a number of cancers establishing the ma-
nipulation of self-renewal mechanisms by malignant
cells to continue disease progression [27-30].
Hedgehog signaling was the first to be implicated in
the maintenance of MM CSCs demonstrating overex-
pression in the pathway both from human myeloma cell
lines and primary human myeloma samples [31]. Bio-
logically, Hedgehog is involved in stem cell maintenance
of ESCs and utilizes a ligand-receptor mechanism of Hh
to Patched 1 (Ptch1) to the receptor Smoothened to in-
duce activation of the pathway [32]. Cyclopamine, which
targets and inhibits Smoothened, was found to induce
apoptosis in MM cells [31]. The use of cyclopamine in
specifically treating cancer stem cells was demonstrated
in lung and prostate cancer studies, inducing apoptosis
and inhibiting growth of the malignant cells [33,34].
One clinical trial utilizing a small molecule inhibitor of
the Hedgehog pathway demonstrated significant re-
sponses in over 50% of advanced metastatic basal cell
carcinoma patients [35]. Another clinical use of this
molecule was performed in a medulloblastoma patient
with some success [36]. However, the clinical use of
Hedgehog inhibitors in treating MM has not been
reported.
The Wnt pathway utilizes 19 conserved glycoproteins
that bind to the transmembrane receptor Frizzled, acti-
vating canonical β-catenin signaling and noncanonical
pathways to induce proliferation and activation [37]. In
fact, genetic manipulation of normal Wnt signaling af-
fects the development and function of multiple organs
[38]. Aberrant activation of the Wnt pathway promotes
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samples [39]. This activation is induced by intracellular
mechanisms and through crosstalk with the BM micro-
environment [40-43]. Small molecule inhibitors of the
Wnt pathway have disrupted the maintenance of MM
cells both in vitro and in vivo providing the possibility of
developing Wnt-targeted inhibitors for clinical treatment
of MM [44,45] gp96 is a molecular chaperone in the
endoplasmic reticulum and it is regulated by the un-
folded protein response pathway [46]. It was shown
recently that gp96 is a critical chaperone for Wnt co-
receptor LRP6 [47]. Targeted inhibition of gp96 genetically
and pharmacologically has shown to be an effective stra-
tegy against multiple myeloma through inhibition of
Wnt-LRP6-surivivin pathway [48].
The Notch signaling pathway is involved in various
cellular events from proliferation, differentiation and
apoptosis to cell maintenance and survival [49]. The ex-
pression of Notch in stem-like populations in various
cancers promotes survival of the CSC and progression
of disease [50-54]. Activation of Notch in MM promotes
proliferation and induces enhanced development of the
disease [55-57]. One study investigated the expression of
Notch on BM clonotypic B cells from MM patients and
found high expression of Notch on these cells indicating
an involvement of Notch signaling in maintaining the
MMSC [58]. Inhibitors of Notch signaling have success-
fully prevented localization and migration of MM cells
to the BM and induced apoptosis of these cells but this
has not been attempted in clinical settings [59-61].
These studies underlie the fact that CSCs, and more
specifically, MMSCs, utilize mechanisms similar to nor-
mal stem cells to survive, maintain disease and increase
progression of disease. Identifying the specific MMSC
population that maintains MM would be advantageous
in developing a therapy unique to targeting these cells.
Recurrence and disease progression
Current therapeutics
Treatment of MM has largely been established through
utilization of chemotherapy. Weder in 1950 published
the first successful treatment of MM through the use of
urethane, an ethyl carbamate that had little success in
treating other hematological malignancies such as
leukemia [62]. The use of melphalan and cyclophospha-
mide and the corticosteroids prednisone and dexametha-
sone enhanced the treatment of MM and the
subsequent combination of these drugs has improved
the treatment response rate and the disease progression-
free survival [63-66]. However, these treatments still did
not produce greater overall survival and long-term re-
mission, requiring the development of better therapies
and treatments [67]. Immunomodulatory agents, thal-
idomide and lenalidomide, both have had promisingresults in improving time to remission and survival in
newly diagnosed and relapsed MM [68,69]. Proteasome
inhibitors such as bortezomib and carfilzomib are ef-
fective in the treatment of multiple myeloma. Autolo-
gous hematopoietic stem cell transplantation has also
been used as therapy in healthy, fit patient population.
Induction chemotherapy combining 2–3 drugs with
immunomudulatory agent, proteasome inhibitor and
corticosteroid, followed by autologous SCT and post-
transplant maintenance therapy has become a gold
standard of therapy for myeloma. This approach has sig-
nificantly improved the response rate and patients’ over-
all outcome. Other novel agents have also emerged for
the treatment of multiple myeloma including HSP90 in-
hibitors [70], Bruton’s tyrosine kinase (BTK) inhibitors
[71], and novel immunomodulating agents [72,73]. Un-
fortunately these therapies have been unable to provide
complete eradication of disease. Nearly all MM patients
will eventually relapse and become resistant to currently
available chemoagents. The exact cause for the relapse
remains to be defined and may vary between individual
patients. One of the possibilities for the relapse is the
persistence of a CSC in myeloma [9]. Many mechanisms
involving CSC dormancy have been proposed including
evasion of anti-tumor immunity by the tumor cell, the
ability of the immune system to control residual tumor
cells and the lack of an optimal microenvironment for
growth [74].
Microenvironment and drug resistance
The capacity for the CSC to remain dormant at length
requires interaction with a specialized niche or micro-
environment for optimal support. It is unknown whether
MMSC resides in BM or in the post-germinal center of
secondary lymphoid organs. It was postulated that simi-
lar to B cells and plasma cells, MMSCs are maintained
at specific niches in the BM for a long-term survival
[75,76]. The BM microenvironment is characterized by
extracellular matrix (ECM) components, including colla-
gens, fibronectin and laminin and cellular parts includ-
ing hematopoietic cells, BM stromal cells, BM
endothelial cells, osteoblasts and osteoclasts [76-78] (See
Figure 1). Extracellular signaling and cell-cell interac-
tions maintain the homeostatic environment and con-
tribute to MM pathogenesis and maintenance. The
various BM stromal cells secrete factors including inter-
leukin 6 (IL6), RANK ligand (RANKL), insulin-like
growth factor 1 (IGF1), tumor necrosis factor alpha
(TNFα), vascular endothelial growth factor (VEGF), B
cell activating factor (BAFF) and stromal cell-derived
factor 1 alpha (SDF1) which are required for normal cell
function and exacerbate MM disease progression
[79-83]. A paracrine loop is stimulated in that MM ad-






















































Figure 1 Similarities of hematopoietic stem cells and multiple myeloma stem cells. The bone marrow microenvironment of normal
(A) and multiple myeloma (B) and the signaling involved in maintaining the cell populations at the niche.
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secretion [84-86].
The bone cellular components, osteoblasts and osteo-
clasts, are involved in MM. Osteoblasts secrete IL6
which induces bone lysis along with MM cell prolifera-
tion [87,88]. They also secrete osteoprotegerin (OPG),
which prevents TRAIL-mediated death in MM cells
[89]. Osteoclasts are involved in bone destruction and
seen to be over proliferative in patients [90]. The cellsare activated by RANKL, IL-3 and IL-6, all of which are
secreted heavily by BM stromal cells [91]. RANK is
expressed on osteoclast progenitor cells, inducing their
differentiation to osteoclasts and further exacerbating
bone lytic damage [92].
Another important mechanism in cell-niche inter-
action of normal and cancer cells are the family of integ-
rins [93]. Very late antigen 4 (VLA-4), which is
composed of α4 and β1, and VLA-5, which includes α5
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and plasma cell adhesion [94,95]. Interestingly, there is a
downregulation of VLA-5 on progressing malignant PCs
and an upregulation of VLA-4 [94]. Binding of VLA-4 to
the niche induces NFκB activation in MM cells and in-
duces a cell adhesion-mediated drug resistance (CAM-
DR) [95]. Interestingly, the overexpression of VLA-4 is
found dramatically in resistant plasma cells. CAM-DR,
initially identified in MM, has been attributed to other
stromal-microenvironment diseases including glioblast-
oma and acute myelogenous leukemia [96,97]. The SDF-
1–CXCR4 signaling pathway also plays a critical role in
MM cell maintenance. CXCR4 knockdown prevented
MM cell line migration to SDF-1 demonstrating the
need for this receptor for proper localization [98,99].
The microenvironment of the BM critically maintains
various different cells, such as HSCs and memory B
cells, for long-term functional responses. Interestingly,
many of the signaling molecules involved in maintaining
self-renewal of HSCs are involved in propagation of MM
indicating that MMSCs may hijack these pathways to
maintain long-term survival and maintenance (Figure 1).
Immune system and tumor dormancy
Though the mechanisms contributing to CSC dormancy
may be collective, the immune system plays an import-
ant role in either inducing suppressive function or being
inhibited by tumor cells. Tumor dormancy has been rec-
ognized in AML, CML and breast cancer, where circu-
lating or residual tumor cells are detected though
complete remission by clinical standards has been dem-
onstrated [100-102]. A classic model of studying dor-
mant CSCs has been with the DA1-3B Bcr-Abl murine
model [103]. Although leukemic cell vaccination by gene
transfer (CD80, CD154 and GM-CSF) can induce a
tumor dormancy phenomenon compatible with long-
term survival, residue disease does persist in a large
number of mice [104]. Over time, the lack of sensitivity
provided an evasion mechanism inducing a more pro-
gressive disease. Further studies have demonstrated that
the resistant tumor cells had altered the immune surveil-
lance mechanisms, changing the response by the host
immune system and providing protection to targeted cell
death [105]. In these tumor studies, blocking CTLA4 en-
hanced CTL-mediated death of tumor cells, a reason for
the development of anti-CTLA4 treatment in the clinic
[106]. Specifically, this phenomenon of immune dor-
mancy and CSCs has been demonstrated in colon car-
cinoma and melanoma [107]. With regard to patients
with MM, evidence of immune suppression is abun-
dantly clear from frequent infections to the development
of secondary malignancies. MM CSCs may evade the
immune system via altering the homeostasis of the vari-
ous cells in the immune compartments.T cells
Early reports have shown that decreases in CD4 and
CD8 T cells negatively correlate with survival in MM
and loss of T cell function was demonstrated in MM pa-
tients indicating an important role for the immune sys-
tem in MM [108,109]. Of recent note, there have been
studies implicating the role of T regulatory (Treg) cells
and Th17 cells in MM pathogenesis (Figure 2). The
role of Tregs in MM has been conflicting as evidence
has pointed to both increased and decreased numbers
of Tregs in MM and MGUS patients [109,110]. Though
differences in identification of Tregs may contribute
to the contradictory results, another study correlated
an increased number of Tregs with advanced patho-
logy and disease progression providing a link between
Treg numbers and disease status [111]. A study into
Th17 cells in the BM of MM patients found there
was a significant increase in numbers compared to
the peripheral blood (PB), a result not seen in MGUS
patients [112]. Elevated levels of Th17 cells can in-
duce myeloma cell proliferation in vitro and in vivo
and the increased levels of IL6 and TGFβ, typically
observed in MM patients, can contribute to the dif-
ferentiation and proliferation of Th17 cells [113]. These
data suggest that T cells may contribute to the high
frequency of relapse in MM patients, inhibiting anti-
tumor immunity and inducing inflammation and pro-
liferation of cells.
MDSCs and NKs
Myeloid-derived suppressor cells (MDSC) are an imma-
ture myeloid population naturally suppressing natural
killer (NK) cells, natural killer T cells (NKT) and anti-
tumor activity induced by T cells. Suppression is induced
by secretion of ROS, COX-2, nitric oxide, IL6 and IL10,
among others. A recent report showed that MDSC pop-
ulations in BM and peripheral blood of MM patients
was dramatically increased compared to control donors,
correlating with disease progression [114]. Conversely,
NK cells, which have cytotoxic activity on tumor cells,
have demonstrated different levels of activity correlating
with MM disease stage [115]. In early stages of disease,
MM has higher expression of NKG2D ligand such as
MHC class I related chain protein A (MICA), indu-
cing NKG2D-triggered cell lysis. However, resistance
to NK lytic mechanisms is incurred upon more pro-
gressive disease with less surface MICA. To further
validate the role of NK cells, another report demon-
strated that levels of NKT cells were significantly de-
creased in advanced stage MM versus early MM,
MGUS or control patients [116]. This suggests that the
cyto-lytic compartment of the immune system is at-






















Figure 2 Bone marrow immunosurveillance and tumor dormancy. The cellular snapshot of normal (A) and multiple myeloma (B) bone
marrow. The influx of cytokines, primarily IL6, into the stroma induces proliferation of cells involved in suppressing anti-tumor activity.
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Many studies have looked into the hypothesis of the
MMSC with regard to disease relapse of MM, however
with little success. The most significant problem is the
difficulty to definitely isolate the MMSC to study the
unique biology of this cell type. Until this occurs, re-
searchers are left trying to understand the progression of
myeloma without knowledge of the start. Though thecomplexities of specific translocations and mutations
in the genetic structure of B cells contribute to the
tumorigenic nature of the MMSC, the cell must reside
in a hospitable niche, to sustain long-term survival.
Understanding the interaction of the MMSC with the
surrounding BM microenvironment will enable us to as-
certain the required elements for MMSC maintenance
and avoidance from therapies. Furthermore, the evasion
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comprehend potential ways of targeting the cell. Inter-
estingly, there are many similarities between the HSC
and MMSC concerning extracellular and intracellular re-
ceptors and signaling. The understanding we have on
the complexities required for self-renewal and mainten-
ance of the HSC in the BM could be applied to the
MMSC to potentially identify and eradicate the cancer
stem cell from the BM environment. Utilizing human
cell products and transferring them into mice does not
allow for efficient studying of the host microenviron-
ment, particularly related to the roles of immune system
in either controlling or later promoting MM. Studies
delving into isolating potential tumorigenic populations
in syngeneic but humanized mouse models would pro-
vide valuable information to study the role of myeloma
disease progression, and put into rest the elusive ques-
tion of the existence of MMSC.
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